

Evgeny Levchenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9018181/publications.pdf>

Version: 2024-02-01

36
papers

5,352
citations

516710

16
h-index

454955

30
g-index

39
all docs

39
docs citations

39
times ranked

6902
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
2	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
3	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
4	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
5	Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103194.	4.4	260
6	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	10.7	206
7	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
8	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	10.7	131
9	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
10	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2208-2217.	1.1	66
11	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. <i>ESMO Open</i> , 2016, 1, e000068.	4.5	54
12	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238.	0.8	39
13	Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. <i>Cancer Letters</i> , 2009, 278, 183-191.	7.2	37
14	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87.	2.0	29
15	Species composition and morphology of dinoflagellates (Dinophyta) of epiphytic assemblages of Peter the Great Bay in the Sea of Japan. <i>Russian Journal of Marine Biology</i> , 2011, 37, 23-32.	0.6	28
16	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	1.2	21
17	A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. <i>Investigational New Drugs</i> , 2020, 38, 457-467.	2.6	16
18	Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases. <i>Onkologie</i> , 2009, 32, 674-677.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Carbon Metabolism Transitions during the Development of Marine Macroalga <i>Gracilaria verrucosa</i> . Russian Journal of Plant Physiology, 2003, 50, 68-72.	1.1	3
20	Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?. Onkologie, 2011, 34, 559-560.	0.8	3
21	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. Journal of Clinical Oncology, 2015, 33, 102-102.	1.6	3
22	Differentiation of Male Gametes in <i>Gracilaria verrucosa</i> (Rhodophyta, Gracilariales). Russian Journal of Marine Biology, 2003, 29, 251-254.	0.6	2
23	Analysis results of combined treatment of patients with verified cancer of the cervical esophagus and hypopharynx with the application of surgical treatment with one-stage defectâ€™s plastic. Opuholi Golovy I Sei, 2016, 6, 61-63.	0.4	2
24	Determination of dihydroxymelphalan in perfusate, blood plasma, and lung tissue by HPLC-MS: Use in a pharmacokinetic study. Journal of Analytical Chemistry, 2014, 69, 377-383.	0.9	1
25	A Study of the Properties of the Multi-Step Recurrent Models for the Interannual Dynamics of Epiphytic Diatom Communities. Russian Journal of Marine Biology, 2018, 44, 580-591.	0.6	1
26	Chondrosarcoma of trachea: case report of successful surgical treatment of local recurrence. Opuholi Golovy I Sei, 2019, 9, 95-98.	0.4	1
27	ADVANCED LARYNGEAL CANCER (LITERATURE REVIEW). Siberian Journal of Oncology, 2019, 18, 97-107.	0.3	1
28	Surgical management of hypopharyngeal cancer (narrative review). Opuholi Golovy I Sei, 2019, 9, 35-42.	0.4	1
29	Characteristics of Patients with Pleural Mesothelioma in the Russian Federation. Value in Health, 2014, 17, A617.	0.3	0
30	EGFR T790M mutation in treatment-naïve tumor samples: Low frequency, evidence for interaction with EGFR TKI-sensitizing mutations and lack of clear predictive value. Annals of Oncology, 2018, 29, vi4.	1.2	0
31	Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2016, 34, 8557-8557.	1.6	0
32	Isolated chemoperfusion of the lung and pleura as a method of treatment in children with common forms of solid bone tumors. Russian Journal of Pediatric Hematology and Oncology, 2019, 6, 40-47.	0.3	0
33	Use of the Hedgehog signaling pathway inhibitor in the treatment of recurrent locally advanced and metastatic basal cell skin cancer. Opuholi Golovy I Sei, 2020, 9, 38-42.	0.4	0
34	Frequency and risk factors of surgical complications in patients with locally advanced cervical esophageal cancer. Medical Alphabet, 2022, , 37-40.	0.2	0
35	Analysis results of surgical treatment and chemoradiotherapy with assessment of prognostic factors in locally advanced laryngeal cancer. Opuholi Golovy I Sei, 2022, 11, 29-34.	0.4	0
36	Comparative analysis results of surgical treatment, chemoradiotherapy and chemotherapy with assessment of prognostic factors in cervical esophageal cancer. Journal of Modern Oncology, 2021, 23, 649-654.	0.3	0